KRAS and Cirrhosis: However, NS3 protease inhibitor-containing regimens are contraindicated in patients with decompensated cirrhosis and in patients with compensated cirrhosis with previous episodes of decompensation because the blood concentrations of these drugs are markedly higher in patients with decompensated cirrhosis [3,4,5].